CNS Pharmaceuticals Company Presentation

CNS pharmaceuticals 6 • We have received positive pre-IND guidance from the FDA. • Our clinical drug supply of Berubicin is nearing completion via a redundant manufacturing strategy with production in the US and in Europe. • We are preparing an IND for filing in Q4 2020. • We plan to initiate a randomized and controlled pivotal U.S. Phase 2 clinical trial of Berubicin for the treatment of GBM in Q1 2021. • Potential for accelerated approval pathway due to desperate unmet clinical need. • Orphan Drug designation received for “Malignant Gliomas” in June 2020. • Clinical trials in Poland (Phase 2 adult and Phase 1 pediatric) expected to begin Q1 2021 at no cost to CNS. • Development agreement with WPD for an anti-viral portfolio with potential COVID-19 applications Berubicin Value Drivers.